Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts

Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules

(2011) Vladimir Tolmachev et al.   BIOCONJUGATE CHEMISTRY

Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties

(2011) H. Wallberg et al.   JOURNAL OF NUCLEAR MEDICINE

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

(2010) Srikala S. Sridhar et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [99mTc(CO)3]+, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation

(2010) Vladimir Tolmachev et al.   BIOCONJUGATE CHEMISTRY

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target

(2010) F. De Vita et al.   CANCER TREATMENT REVIEWS

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

(2010) S. Minner et al.   CLINICAL CANCER RESEARCH

Radionuclide Molecular Imaging Using Affibody Molecules

(2010) Sara Ahlgren et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue

(2010) Vladimir Tolmachev et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

(2010) J. Löfblom et al.   FEBS LETTERS

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

(2010) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of99mTc-Labeled Anti-HER2 Affibody Molecules

(2008) Thuy A. Tran et al.   BIOCONJUGATE CHEMISTRY

Slow Internalization of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2 : Implications for Development of Labeled Tracers

(2008) Helena Wållberg et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

(2008) Dorte Lisbet Nielsen et al.   CANCER TREATMENT REVIEWS

Imaging of HER-2 Overexpression in Tumors for Guiding Therapy

(2008) V. Tolmachev   CURRENT PHARMACEUTICAL DESIGN

Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake

(2008) Torun Ekblad et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression

(2008) Clemens Decristoforo et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold

(2008) Per-Åke Nygren   FEBS Journal

The Synthesis and Chelation Chemistry of DOTA−Peptide Conjugates

(2007) Luis M. De León-Rodríguez et al.   BIOCONJUGATE CHEMISTRY